AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06690463 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: sacroiliac joint injection
Description: The procedure involves the administration of a 2.5 cc injection of 2% lidocaine to the sacroiliac joint, targeting the articular or periarticular areas. The injection is performed under real-time ultrasound guidance to ensure accurate placement of the needle.~The 2% lidocaine solution is injected into both the joint space (articular area) and the surrounding soft tissues (periarticular area), which may include ligaments, capsules, and adjacent muscles. The goal is to temporarily anesthetize the joint and surrounding structures to assess the contribution of the sacroiliac joint in the patient's pain, as well as to provide therapeutic pain relief. The use of ultrasound ensures minimal risk of injury to surrounding structures and enhances the accuracy of the injection.~This intervention is commonly used in both diagnostic and therapeutic settings, helping to confirm the role of the sacroiliac joint in a patient's symptoms and providing relief in cases of sacroiliac joint dysfunction.
Study NCT06690177 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: EscharEx (EX-03)
Description: a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
Study NCT06690177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EscharEx (EX-03)
Description: a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
Study NCT06690177 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (Gel vehicle)
Description: A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
Study NCT06690177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Gel vehicle)
Description: A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
Study NCT06687187 — intervention group
Intervention type: DRUG
Intervention: Neostigmine
Description: two groups (Group I, n= 41) and (Group II, n= 43) received varying doses of neostigmine (1 mg and 2 mg respectively
Study NCT06685991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered intravenously at varying times during anesthesia induction to assess the impact of timing on postoperative outcomes. Participants will be randomized into one of three groups: one group will receive dexamethasone before the administration of fentanyl, a second group will receive it after the administration of a muscle relaxant, and a third control group will not receive dexamethasone. This timing variation aims to determine the optimal administration point to improve outcomes, including postoperative nausea, pain, glycemic stability, and hemodynamic response.
Study NCT06685991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered intravenously at varying times during anesthesia induction to assess the impact of timing on postoperative outcomes. Participants will be randomized into one of three groups: one group will receive dexamethasone before the administration of fentanyl, a second group will receive it after the administration of a muscle relaxant, and a third control group will not receive dexamethasone. This timing variation aims to determine the optimal administration point to improve outcomes, including postoperative nausea, pain, glycemic stability, and hemodynamic response.
Study NCT05868655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with Video-Based
Description: A program of stability and balance exercises will be provided
Study NCT05868655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standart exercise-Home-Based
Description: Participants will be asked to take the final measurements after the exercises have been monitored by a physical therapist for eight weeks.
Study NCT06695234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Awareness Training
Description: A second-generation mindfulness-based intervention that reincorporates Buddhist wisdom concepts into mindfulness-based intervention.
Study NCT06691568 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air purifier
Description: Purifiers were turned on for the active group and off for the placebo
Study NCT06691568 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Air purifier
Description: Purifiers were turned on for the active group and off for the placebo
Study NCT06686576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QL1706
Description: Phase Ib/Ⅲ： QL1706 will be administered
Study NCT06686576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPEOX
Description: Phase Ⅲ：CAPEOX will be administered
Study NCT05691361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-324
Description: siRNA duplex oligonucleotide
Study NCT05691361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline
Study NCT05528445 — intervention group
Intervention type: DEVICE
Intervention: Neurosteer EEG recorder
Description: The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
Study NCT04677153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test and treat plus peer mentors
Description: Rapid start of HCV treatment at OTP within days of HCV diagnosis. Participants will receive 8 weeks of glecaprevir/pibrentasvir and will work with a peer mentor during and after treatment.
Study NCT04677153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants are referred to another location for HCV treatment.
Study NCT06340698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience intervention
Description: Contents of the first session include:~1. Resilience. Know the concept of resilience.~2. Stigma management. Discuss stigma experience and learn stigma management strategies such as normalizing the disease.~3. Self-efficacy. Learn ways of improving self-efficacy, such as experience of success and social support.~Contents of the second session include:~1. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions. Learn effective communication skills.~2. Acquiring social support. Know people and resources that could provide support when having HIV-related difficulties and mental health problems.~3. Emotional regulation. Understand the physiological responses to emotions. Know a range of emotional regulation strategies, such as cognitive reappraisal and deep breathing.
Study NCT06340698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence intervention
Description: Contents of the first session include:~1. Adherence behavioral skills. Identify barriers to optimal HAART adherence. Know behavioral skills that can deal with these barriers, such as forgetting, afraid of others' questioning and side effects.~2. Adherence information and motivation. Know how the HIV virus attack human body and the mechanisms of HAART medication. Understand the influence of adherence level on health outcomes.~Contents of the second session include:~1. Adherence motivation. Discuss possibilities and hope of future life, intimate relationship and career.~2. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions concerning HAART medication. Learn effective communication skills.~3. Acquiring social support. Know people and resources that could provide support when having HAART-related difficulties and problems.
Study NCT06438250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-JH04
Description: The dose will be 148-222 MBq given intravenously.
Study NCT06003790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-001
Description: Use of device 3 times per week for 8 weeks - for a total of 24 sessions.
Study NCT05825001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive active EFT stimulus
Study NCT05825001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention (control)
Description: Receive control EFT stimulus
Study NCT05825001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Use iCOquit Smokerlyzer carbon monoxide monitor
Study NCT05825001 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Use iCOquit Smokerlyzer carbon monoxide monitor
Study NCT05454566 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ICM-203
Description: Intra-articular injection
Study NCT06370351 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SENS-501 administration
Description: Administration of SENS-501 with a dedicated administration system
Study NCT06546696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Competency Based Approaches to Community Health (COACH)
Description: COACH is a multi-level intervention, consisting of 1) developmentally appropriate health curriculum for children; 2) family-based content that both targets parent weight loss and leverages a shared parent-child experience to improve family health behaviors; 3) community-level intervention to improve access and quality of family-based programming at local Parks and Rec centers.
Study NCT06546696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competency Based Approaches to Community Health (COACH)
Description: COACH is a multi-level intervention, consisting of 1) developmentally appropriate health curriculum for children; 2) family-based content that both targets parent weight loss and leverages a shared parent-child experience to improve family health behaviors; 3) community-level intervention to improve access and quality of family-based programming at local Parks and Rec centers.
Study NCT05008224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV administered on Day 1 of each 3-week cycle for 3 cycles during pembrolizumab monotherapy.~400 mg IV administered on Day 1 of each 6-week cycle for 4 cycles as pembrolizumab consolidation.
Study NCT05008224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles in all participants after PET scan 2 and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).~35 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive, \<60 years of age).
Study NCT05008224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 6 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).
Study NCT05008224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).
Study NCT05008224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10 units/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Study NCT05008224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Days 1-3 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Study NCT05008224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1250 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Study NCT05008224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Study NCT05008224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Description: 100 mg/m\^2 orally (PO) administered as part of escBEACOPP chemotherapy on Days 1-7 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Study NCT05008224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m\^2 PO administered as part of escBEACOPP chemotherapy on Days 1-14 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Study NCT05142319 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Homologous mRNA booster vaccine
Description: Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
Study NCT05142319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heterologous mRNA booster vaccine
Description: Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
Study NCT05142319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAXIN
Description: Single intradermal injection at 6ug (0.5ml) per dose.
Study NCT05075057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Description: three doses of inactivated COVID-19 vaccine
Study NCT05142319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nuvaxovid
Description: Single intradermal injection at 5mcg (0.5mL) per dose.
Study NCT06291701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of scapular endurance
Description: For the assessment of scapular endurance, participants will be instructed to bend their arms and elbows while keeping a wooden rod placed between their elbows, pull a spring dynamometer placed between thei
Study NCT06291701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prone Bridge Test
Description: For the Prone Bridge Test, participants will be instructed to lie face down with their hands and feet shoulder-width apart and then raise their bodies off the ground by lifting themselves up on their hands, forearms, and toes. A stopwa
Study NCT06291701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Side Bridge Test
Description: For the Side Bridge Test, participants will be asked to lie on their right side, supporting themselves on their forearm and elbow, and lift themselves off the ground. A stopwatch will be started, and the test will be terminated if there is any deviation from the position. The elapsed time will be recorded in seconds. The test will then be repeated on the left side.
Study NCT06291701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Closed Kinetic Chain Upper Extremity Stability Test
Description: For the Closed Kinetic Chain Upper Extremity Stability Test, participants will be asked to assume a push-up position on a flat surface with their hands placed on two parallel lines drawn 90 cm apart. They will then be instructed to touch one hand to the other hand's side as many times as possible within 15 seconds. The test will be repeated three times, and the average of the scores will be calculated.
Study NCT05862584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Distribution of questionnaires to patients to be completed on a weekly basis.
Study NCT04838197 — intervention group
Intervention type: OTHER
Intervention: Questionnaires and Surveys
Description: Quantitative questionnaires will measure and quantify the importance of the various factors (e.g., intensity of dependence, duration of care, health literacy, physical well-being, emotional well-being, social well-being, and financial well-being) that contribute to caregiver burden both preoperatively and postoperatively at 48 hours, 1 week, 2 weeks, and 1 month.
Study NCT05736406 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2
Description: 5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 200 J/cm\^2.
Study NCT05736406 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2
Description: 5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 400 J/cm\^2.
Study NCT05871996 — intervention group
Intervention type: OTHER
Intervention: Palliative Care and Oncology Survey on Terminology (POST)
Description: Each group receives a survey to complete. The only difference between the two is the inclusion criteria; the surveys are the same.
Study NCT04957355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) or Functional electrical stimulation (FES)
Description: Stance and Walk-Perturbation Training Protocol ActiveStep and Surefooted Protocol: Perturbation training protocol with and without FES Participants will be asked to perform a postural disturbance protocol in the stance position and walk in the form of 7 slips and 7 trips with two retention trials after the training using the ActiveStep treadmill system while fitted in a safety harness. All perturbations will be delivered at each participant's comfortable walking speed. Similar slip and trip training in walking will be conducted on the surefooted platform with and without FES.~Gait Training Protocol and Surefooted protocol Participants will be asked to perform a 10m walking test (walking for a distance of 45 feet) in a laboratory environment six times (three times with and without FES) and in an outdoor environment located in the parking lot of the Applied Health Science building (1919 W. Taylor St., Chicago, IL)
Study NCT06274567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial magnetic stimulation (TMS) is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study uses intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).
Study NCT06274567 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham (placebo) TMS
Description: Sham stimulation works by blocking the magnetic field with an internal spacer on the sham side of the TMS coil, allowing the operator to place the coil surface against the scalp. A brief electric pulse calibrated to the stimulator output is delivered to the scalp simultaneous to the TMS pulse to mimic the scalp sensation during the sham condition. 75 Importantly, the electric pulse is calibrated to the stimulator output to ensure a realistic sham condition.
Study NCT05584137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX26
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
Study NCT05584137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Humanized Anti-Programmed Death-1 Monoclonal Antibody
Study NCT04811573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU-sourced Otezla®
Description: Test product
Study NCT05679622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: In the induction stage of UC, FMT group received FMT and PEN intervention, and FMT group are given for at least one course of FMT treatment. If repeated FMTs are received, it is usually at a 2 month interval. All the participants received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) intervention to help induce and maintain clinical remission.
Study NCT04811573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-sourced Otezla®
Description: Reference product 1
Study NCT04811573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Japan-sourced Otezla®
Description: Reference product 2
Study NCT06291701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Seated Medicine Ball Throw Test
Description: For the Seated Medicine Ball Throw Test, participants will be asked to sit on the ground with their back, shoulders, and head against the wall. Holding a 2 kg medicine ball with both hands, they will start with their elbows bent and arms at their sides, then extend their elbows to throw the ball forward as far as possible. The distance between the wall and the point where the ball lands will be recorded. The test will be performed three times, and the average will be calculated.